| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | DBA5; L35A |
| WB Predicted band size | 13 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Full length fusion protein |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于FNDC5抗体的3篇代表性文献及其摘要概括：
---
1. **"A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis"**
*Authors: Boström P, et al. (2012)*
**摘要**：该研究首次发现运动诱导的肌肉因子Irisin(由FNDC5剪切产生)，并开发了针对FNDC5/Irisin的多克隆抗体，通过Western blot和免疫沉淀技术验证了其在白色脂肪褐变中的作用。
2. **"Irisin: Still chasing shadows"**
*Authors: Albrecht E, et al. (2015)*
**摘要**：文章评估了多种商业FNDC5/Irisin抗体的特异性，发现部分抗体存在交叉反应性，提示需谨慎选择抗体以确保检测结果的可靠性，强调标准化抗体验证的必要性。
3. **"Exercise-linked FNDC5/irisin rescues synaptic plasticity and memory defects in Alzheimer’s models"**
*Authors: Lourenco MV, et al. (2019)*
**摘要**：研究利用FNDC5抗体检测小鼠脑组织中FNDC5的表达，发现运动通过上调FNDC5/Irisin改善阿尔茨海默病模型的突触可塑性和认知功能，揭示了其神经保护机制。
---
**备注**：若需更多应用案例，可补充针对抗体开发的研究(如单克隆抗体制备文献)。建议通过PubMed或Web of Science以“FNDC5 antibody validation”为关键词扩展检索。
FNDC5 (fibronectin type III domain-containing protein 5) is a transmembrane protein precursor of irisin, a hormone-like peptide implicated in metabolic regulation, energy expenditure, and adipose tissue browning. Irisin is proteolytically cleaved from FNDC5 and secreted into circulation, primarily in response to exercise. Research on FNDC5/irisin has surged due to its potential role in obesity, diabetes, and metabolic disorders, driving demand for specific FNDC5 antibodies.
FNDC5 antibodies are critical tools for detecting the protein in various applications, including Western blotting, immunohistochemistry (IHC), and ELISA. They target specific epitopes within FNDC5’s structure, such as its N-terminal signal peptide, fibronectin III domain, or the irisin cleavage region. However, challenges persist due to FNDC5’s low basal expression levels and antibody specificity issues, which have led to inconsistencies across studies. Some antibodies may cross-react with unrelated proteins, necessitating rigorous validation using knockout controls.
Commercial FNDC5 antibodies are often raised in rabbits or mice against synthetic peptides or recombinant protein fragments. Their utility spans basic research—exploring FNDC5’s role in muscle-liver-adipose crosstalk—and clinical studies, such as correlating irisin levels with metabolic health. Recent work also investigates FNDC5’s neuroprotective effects and links to bone metabolism. As interest grows, optimizing antibody specificity remains pivotal for elucidating FNDC5’s physiological and therapeutic relevance.
×
